Please login to the form below

Not currently logged in
Email:
Password:

Vimizim

This page shows the latest Vimizim news and features for those working in and with pharma, biotech and healthcare.

BioMarin's real world data sways NICE on orphan drug Vimizim

BioMarin's real world data sways NICE on orphan drug Vimizim

BioMarin's real world data sways NICE on orphan drug Vimizim. Rare genetic disorder treatment recommended in final draft guidance. ... real world data for Vimizim, which was being assessed under NICE's highly specialised technologies programme.

Latest news

  • BioMarin drug boosts growth in children with dwarfism BioMarin drug boosts growth in children with dwarfism

    BioMarin is a rare disease specialist and already sells several products including Vimizim (elosulfase alfa) for mucopolysaccharidosis (MPS) type IVA and Naglazyme (galsulfase) for MPS type VI.

  • Sanofi and Regeneron pay $67.5m to speed alirocumab review Sanofi and Regeneron pay $67.5m to speed alirocumab review

    California-based BioMarin was awarded the voucher in February, when it received approval for Vimizim, a new biological product for patients with the rare disease Mucopolysaccharidosis type IVA, also known as

  • EC approves Biomarin rare genetic disorder drug EC approves Biomarin rare genetic disorder drug

    EC approves Biomarin rare genetic disorder drug. Vimizim now available to treat Morquio A syndrome. ... BioMarin has won EU approval to market its drug Vimizim for the rare genetic disorder Morquio A syndrome.

  • FDA backs BioMarin drug for rare enzyme disorder FDA backs BioMarin drug for rare enzyme disorder

    FDA backs BioMarin drug for rare enzyme disorder. Vimizim is first drug approved in US under rare paediatric disease priority review. ... Marketing applications for Vimizim are also currently under review in the EU, Brazil, Australia, Canada and Mexico. .

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Sales of the product will fit well into BioMarin's commercial infrastructure for its enzyme replacement therapies Naglazyme (galsulfase), for the treatment of Mucopolysaccharidosis VI, and Vimizim (elosulfase alfa) for Morquio

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Nektar Therapeutics appoints Jeff Ajer Nektar Therapeutics appoints Jeff Ajer

    officer. There he worked on establishing BioMarin’s global footprint and commercial infrastructure and has played a leadership role in the launches and growth strategies for brands including Brineura, Vimizim, Kuvan

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics